Profilactic usage of N-acetyl cysteine in the treatment of tuberculosis in children may be effective in protection from hepatotoxicity: A case experience

Abstract

Tuberculosis (TB) disease: Despite developed advanced diagnostic methods and new treatments, its frequency is increasing especially in developing countries and continues to cause death worldwide. Most of the drugs used in the disease process are hepatotoxic. These drugs are generally well tolerated, but their simultaneous use enhances each other’s hepatotoxic effect. The toxic hepatitis that develops during treatment, affects treatment compliance and treatment results can be fatal when it is not noticed, and adequate precautions are not taken. In our case, we wanted to report the protective effect of adding oral N-acetyl cysteine to quadruple (izoniazid, rifampicin, pyrazinamide, and ethambutol) TB treatment against recurrent hepatotoxicity that occurs during the treatment of TB.